Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia

Rhea-AI Summary

Biophytis SA (Euronext Growth Paris:ALBPS) has announced the expansion of its partnership strategy in Asia by signing two contracts with local agents. One contract covers Japan and South Korea, while the other focuses on China and Southeast Asia. These agents will help Biophytis identify partners for its drug candidate BIO101 (20-hydroxyecdysone) in these markets.

This initiative aims to accelerate BIO101's deployment in Asia, the world's second-largest pharmaceutical market. Japan and China are strategic targets due to their high prevalence of sarcopenia and obesity, respectively. Following a recent exclusive license agreement with Blanver in Latin America, Biophytis now seeks co-development and commercialization agreements with partners in Asia and North America.

Positive

• Expansion into Asian markets through local agent partnerships
• Targeting Japan and China, key markets for sarcopenia and obesity treatments
• Recent exclusive license agreement signed with Blanver for Latin America

Negative

• None.

Financial Analyst

Biophytis' announcement of partnerships with local agents in Asia is a strategic move to expand into the world's second-largest pharmaceutical market. This initiative aligns with their recent exclusive license agreement in Latin America, suggesting a focused global expansion strategy. By leveraging local networks, Biophytis can accelerate the deployment of BIO101, potentially increasing market share and revenue. However, this approach involves risks such as the efficacy of local agents and regulatory hurdles. For investors, the short-term impact might be neutral until concrete results, like partnership agreements or clinical trial advancements, materialize. Long-term, successful integration into Asian markets could significantly enhance company valuation and revenue streams.

Market Research Analyst

The strategic partnerships Biophytis has signed in Asia are important for penetrating markets like Japan and China, where there is a significant prevalence of age-related diseases such as sarcopenia and obesity. These partnerships can expedite the commercialization process of BIO101 by utilizing established networks within these regions. However, the effectiveness of these partnerships will heavily depend on how well the local agents can navigate the complex pharmaceutical landscape and establish meaningful collaborations. For retail investors, this development shows Biophytis' commitment to global expansion, which is positive, but the true impact will be seen only with subsequent successful collaborations and market penetration.

Medical Research Analyst

Biophytis' focus on sarcopenia and obesity in its Asian expansion strategy is well-founded given the high prevalence of these conditions in Japan and China. The company’s drug candidate BIO101, which targets age-related diseases, addresses a critical need in these populations. By signing contracts with local agents, Biophytis can effectively reach out to potential partners for co-development and commercialization, speeding up the drug's market entry. For investors, the medical implications are promising, but success will depend on how quickly and effectively these partnerships translate into clinical trials and drug approvals in the targeted regions.

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strategy in Asia.

To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These agents will leverage their networks within the pharmaceutical sector to support Biophytis in identifying partners for the drug candidate BIO101 (20-hydroxyecdysone) in these different countries.

This initiative is part of the partnership development strategy in Asia, aimed at accelerating the deployment of BIO101 in this key geography, the second largest pharmaceutical market in the world. Biophytis is determined to establish successful collaborations to meet patients' needs and make significant advances in the various targeted pathologies.

Japan and China are two strategic markets for Biophytis. Indeed, Japan has the largest population in the world suffering from sarcopenia, with more than 1 in 5 people aged 60 and over affected (source: Yuan 2023, Epidemiology of Sarcopenia, Metabolism). Additionally, more than 70 million Chinese adults are affected by obesity, making it the second-largest population worldwide with this pathology (source: https://www.worldobesity.org/).

Following the exclusive license agreement signed with Blanver, one of the leading pharmaceutical companies in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin America, Biophytis aims to sign new co-development and commercialization agreements with industrial partners in Asia and also in North America, the world's largest pharmaceutical market.

****

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy, phase 1-2 study to be started, respiratory (Covid-19, phase 2 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825). For more information, visit www.biophytis.com

Forward-looking statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts Biophytis

Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com

Media

Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50

SOURCE: Biophytis

View the original press release on accesswire.com

FAQ

What partnerships has Biophytis (BPTS) announced on July 22, 2024?

Biophytis announced two contracts with local agents: one for Japan and South Korea, and another for China and Southeast Asia, to help identify partners for their drug candidate BIO101 in these markets.

What is the main purpose of Biophytis' (BPTS) partnership strategy in Asia?

The main purpose is to accelerate the deployment of BIO101 (20-hydroxyecdysone) in Asia, which is the second-largest pharmaceutical market globally, and to establish collaborations to meet patients' needs in various targeted pathologies.

Why are Japan and China important markets for Biophytis (BPTS)?

Japan has the largest population suffering from sarcopenia globally, with over 20% of people aged 60+ affected. China has the second-largest population of adults with obesity, making these countries strategic markets for Biophytis' drug candidate BIO101.

What recent agreement did Biophytis (BPTS) sign in Latin America?

Biophytis recently signed an exclusive license agreement with Blanver, a leading pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin America.